Information about actively enrolling, ongoing, and completed clinical trials of cancer prevention, early detection, and supportive care, including phase I, II, and III agent and action trials and clinical trials management.
Hi, my name is Raffaellina and [am here] thanks to the European Institute of Oncology and to the research! I am 76 years old and I have been diagnosed [with] breast cancer. I have chosen to participate into a clinical trial because of the clear and accurate explanation of my options and future perspectives and for the confidence in research transmitted by the Team I felt as a” human being” and not as a “number”, and this feeling has not changed afterwards. I was so scared about my future, but when the team proposed me to participate in the study, I have accepted it with enthusiasm. No adverse event occurred, and moreover, I have experienced benefit that impacted the definitive surgery. We need to trust and support clinical research!
Type(s) of Trial: Prevention
Trial Link(s): Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
Monograph on Engaging Older Adults in Clinical Trials
A JNCI monograph on Engaging Older Adults in Cancer Clinical Trials Conducted in the National Cancer Institute Clinical Trials Network. The articles, developed through working groups formed for an NCI workshop held in April 2021 to address this issue, provide recommendations and new and innovative solutions to common barriers to accrual.
Researchers Search the Genome for Clues to Early Age Onset Cancers in Racial/Ethnic Minorities
While researchers have identified some of the genetic changes that lead to cancer development, a key knowledge gap remains: finding the genetic changes that drive the development of cancers that arise at an earlier age than average (early onset) in racially and ethnically diverse populations.
New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development
The National Cancer Institute is leading a project to create a cohort of people who are newly diagnosed with diabetes in the hopes that this group, who are at increased risk of developing pancreatic cancer, provide the clues in their blood and tissues to unravel some of the unknowns about this highly fatal cancer. The New Onset Diabetes Study (NOD) will include 10,000 people ages 50 to 85 across the United States.